Molbio Diagnostics has announced a strategic global collaboration with UE LifeSciences to expand the reach of iBreastExam, a radiation-free, painless, and FDA-cleared breast cancer screening device, to more than 50 countries across Asia, Africa, and beyond. This partnership represents a major step forward in making early detection accessible to millions of women who face barriers to traditional screening methods.
Breast cancer remains the leading cancer among women worldwide, and late detection is one of the most significant factors contributing to mortality. By combining Molbio’s extensive global distribution network with UE LifeSciences’ innovative technology, this collaboration aims to transform the landscape of breast cancer screening in low- and middle-income regions.
iBreastExam is a portable, battery-operated point-of-care device that can identify breast lumps in minutes without pain, radiation, or the need for specialized infrastructure. Using advanced sensor technology, it automates physical examination, ensuring accuracy without requiring interpretation from the user. With cloud-enabled storage for seamless follow-up, it is designed for use in primary healthcare settings, outreach programs, and mass screening campaigns, particularly in communities where access to mammograms is limited or non-existent.
Mihir Shah, Founder and CEO of UE LifeSciences, emphasized the importance of this initiative, highlighting that Molbio’s strong market presence and experienced team will help amplify their shared mission to improve women’s health outcomes globally. Molbio’s track record of delivering innovative diagnostic solutions, including the WHO-endorsed Truenat PCR platform, positions the company as a strong partner to scale the reach of iBreastExam.
The collaboration will focus on rolling out the device across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam, creating new opportunities for early intervention and saving countless lives through timely diagnosis.
This partnership is not just about technology—it is about bridging gaps in access to healthcare, empowering women, and ensuring that early detection of breast cancer is no longer a privilege, but a global reality.
